Oral Semaglutide Benefits: EMA Approves First O...

By HEOR Staff Writer

September 16, 2025

Novo Nordisk’s oral semaglutide (Rybelsus®) has received a significant label update from the European Medicines Agency (EMA). It is now the first and only oral glucagon-like peptide-1 receptor agonist (GLP-1 RA) approved in the EU for type 2 diabe...
Insights on GLP-1 Therapy in Bariatric Surgery Patients
Evolving Strategies in Type 2 Diabetes Management: NICE Guideline Update 2025
Building a Better Ecosystem for Digitally Enabled Diabetes Care in Europe
Comprehensive Review of Type 2 Diabetes Treatment and Diagnosis Strategies
T1 Diabetes Care with an Implantable Glucose Device
Business Dynamics: How Novo Nordisk Lost GLP-1 Market Share
Another GLP-1 Drug Access Model: Will a Co-Pay Cap Revolutionize Affordability?
Market Leadership in Sight as Eli Lilly’s Oral GLP-1 Medication Orforglipron ...
A Shared-Value Model for Enhancing Diabetes Care in South Africa
Improving Diabetes Medicine Access: Key Changes in the Pharmaceutical Benefit...
NovoCare and the Rise of Direct-to-Consumer Pharmaceutical Access
Cost Savings and Impact of Comprehensive Medication Management in Healthcare